A transient amphipathic helix in the prodomain of PCSK9 facilitates binding to low-density lipoprotein particles

The Elusive Inhibitory Function of the Acidic N-Terminal Segment of the Prodomain of PCSK9: The Plot Thickens

(2019) Nabil G. Seidah   JOURNAL OF MOLECULAR BIOLOGY

Identification of a Helical Segment within the Intrinsically Disordered Region of the PCSK9 Prodomain

(2019) M. Ultsch et al.   JOURNAL OF MOLECULAR BIOLOGY

Cell-associated heparin-like molecules modulate the ability of LDL to regulate PCSK9 uptake

(2018) Adri M. Galvan et al.   JOURNAL OF LIPID RESEARCH

Stepwise processing analyses of the single-turnover PCSK9 protease reveal its substrate sequence specificity and link clinical genotype to lipid phenotype

(2017) John S. Chorba et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Threshold Effects of Circulating Angiopoietin-Like 3 Levels on Plasma Lipoproteins

(2017) Sergio Fazio et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Heparan sulfate proteoglycans present PCSK9 to the LDL receptor

(2017) Camilla Gustafsen et al.   Nature Communications

PCSK 9 gain-of-function mutations (R496W and D374Y) and clinical cardiovascular characteristics in a cohort of Turkish patients with familial hypercholesterolemia

(2017) Esra Kaya   Anatolian Journal of Cardiology

Carriers of the PCSK9 R46L Variant Are Characterized by an Antiatherogenic Lipoprotein Profile Assessed by Nuclear Magnetic Resonance Spectroscopy—Brief ReportHighlights

(2016) Rutger Verbeek et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Recognition of the disordered p53 transactivation domain by the transcriptional adapter zinc finger domains of CREB-binding protein

(2016) Alexander S. Krois et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

On the function and homeostasis of PCSK9: Reciprocal interaction with LDLR and additional lipid effects

(2015) Hagai Tavori et al.   ATHEROSCLEROSIS

Characterization of Autosomal Dominant Hypercholesterolemia Caused byPCSK9Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal AntibodyCLINICAL PERSPECTIVE

(2015) Paul N. Hopkins et al.   Circulation-Cardiovascular Genetics

Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor

(2015) Rocco Romagnuolo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Removal of Plasma Mature and Furin-Cleaved Proprotein Convertase Subtilisin/Kexin 9 by Low-Density Lipoprotein-Apheresis in Familial Hypercholesterolemia: Development and Application of a New Assay for PCSK9

(2015) Mika Hori et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Intrinsically disordered proteins in cellular signalling and regulation

(2015) Peter E. Wright et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Characterisation of de novo mutations in the C-terminal domain of proprotein convertase subtilisin/kexin type 9

(2015) S. Geschwindner et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Characterization of Autosomal Dominant Hypercholesterolemia Caused byPCSK9Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal AntibodyCLINICAL PERSPECTIVE

(2015) Paul N. Hopkins et al.   Circulation-Cardiovascular Genetics

Reduction of Low-Density Lipoprotein Cholesterol by Monoclonal Antibody Inhibition of PCSK9

(2014) Evan A. Stein et al.   Annual Review of Medicine

A Million Peptide Motifs for the Molecular Biologist

(2014) Peter Tompa et al.   MOLECULAR CELL

Disorder and residual helicity alter p53-Mdm2 binding affinity and signaling in cells

(2014) Wade Borcherds et al.   Nature Chemical Biology

Structural Basis of Receptor Sulfotyrosine Recognition by a CC Chemokine: The N-Terminal Region of CCR3 Bound to CCL11/Eotaxin-1

(2014) Christopher J. Millard et al.   STRUCTURE

Insights Into PCSK9, Low-Density Lipoprotein Receptor, and Low-Density Lipoprotein Cholesterol Metabolism

(2013) Evan A. Stein et al.   CIRCULATION

Serum Proprotein Convertase Subtilisin/Kexin Type 9 and Cell Surface Low-Density Lipoprotein Receptor

(2013) Hagai Tavori et al.   CIRCULATION

The Multifaceted Proprotein Convertases: Their Unique, Redundant, Complementary, and Opposite Functions

(2013) Nabil G. Seidah et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation

(2013) Tanja Kosenko et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts

(2013) My-Anh Nguyen et al.   JOURNAL OF LIPID RESEARCH

An Antibody against the C-Terminal Domain of PCSK9 Lowers LDL Cholesterol Levels In Vivo

(2013) Felix Schiele et al.   JOURNAL OF MOLECULAR BIOLOGY

Scalable web services for the PSIPRED Protein Analysis Workbench

(2013) Daniel W. A. Buchan et al.   NUCLEIC ACIDS RESEARCH

Proprotein Convertase Subtilisin/Kexin Type 9 Interacts With Apolipoprotein B and Prevents Its Intracellular Degradation, Irrespective of the Low-Density Lipoprotein Receptor

(2012) Hua Sun et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Removal of acidic residues of the prodomain of PCSK9 increases its activity towards the LDL receptor

(2011) Øystein L. Holla et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Effects of the Prosegment and pH on the Activity of PCSK9

(2010) Suzanne Benjannet et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PCSK9R46L, Low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease

(2010) Marianne Benn et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The protein meta-structure: a novel concept for chemical and molecular biology

(2009) Robert Konrat   CELLULAR AND MOLECULAR LIFE SCIENCES

Linking folding and binding

(2009) Peter E Wright et al.   CURRENT OPINION IN STRUCTURAL BIOLOGY

Degradation of LDLR protein mediated by ‘gain of function’ PCSK9 mutants in normal and ARH cells

(2008) Tommaso Fasano et al.   ATHEROSCLEROSIS

PCSK9 is phosphorylated by a Golgi casein kinase-like kinase ex vivo and circulates as a phosphoprotein in humans

(2008) Thilina Dewpura et al.   FEBS Journal

Cholesterol feedback: from Schoenheimer's bottle to Scap's MELADL

(2008) Michael S. Brown et al.   JOURNAL OF LIPID RESEARCH

Plasma PCSK9 preferentially reduces liver LDL receptors in mice

(2008) Aldo Grefhorst et al.   JOURNAL OF LIPID RESEARCH

PCSK9: a convertase that coordinates LDL catabolism

(2008) Jay D. Horton et al.   JOURNAL OF LIPID RESEARCH

Molecular basis for LDL receptor recognition by PCSK9

(2008) H. J. Kwon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor

(2008) D.-W. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA